Last reviewed · How we verify
Dexamethasone Cipecilate (DEXAMETHASONE ACEFURATE)
Dexamethasone Cipecilate (generic name: DEXAMETHASONE ACEFURATE) is a Corticosteroid drug. It is currently in Phase 2 development.
Dexamethasone Cipecilate works by binding to glucocorticoid receptors in the body, which helps to reduce inflammation and suppress the immune system.
Dexamethasone Cipecilate, also known as Dexamethasone Acefurate, is a corticosteroid small molecule. It is a synthetic derivative of cortisol, a naturally occurring hormone in the body. The exact target of Dexamethasone Cipecilate is unknown, but it is used to treat various inflammatory conditions. Its commercial status is currently unclear, and it may be patented or have generic manufacturers. As a corticosteroid, it has key safety considerations, including potential side effects such as increased blood sugar levels and changes in blood pressure.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DEXAMETHASONE ACEFURATE |
|---|---|
| Drug class | Corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's immune system as a fire alarm that goes off when it senses danger. Dexamethasone Cipecilate is like a fire alarm silencer that reduces the alarm's sensitivity, helping to calm down the immune response and reduce inflammation. This can be helpful for people with conditions like arthritis or asthma, but it's not suitable for everyone and can have side effects.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone Cipecilate CI brief — competitive landscape report
- Dexamethasone Cipecilate updates RSS · CI watch RSS
Frequently asked questions about Dexamethasone Cipecilate
What is Dexamethasone Cipecilate?
How does Dexamethasone Cipecilate work?
What is the generic name of Dexamethasone Cipecilate?
What drug class is Dexamethasone Cipecilate in?
What development phase is Dexamethasone Cipecilate in?
Related
- Drug class: All Corticosteroid drugs
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing